Now
available
Redefine the
patient experience
post-dilation
Offer your patients the only commercially
available FDA-approved product that reverses pharmacologically-induced mydriasis.1
RYZUMVI is the first and only relatively non-selective alpha-1 and alpha-2 adrenergic antagonist approved to reverse pharmacologically-induced mydriasis.1
RYZUMVI reversibly binds to alpha-1 adrenergic receptors on the radial iris dilator muscle, thereby reducing pupil diameter, and indirectly reverses mydriasis induced by muscarinic antagonist effects on the iris sphincter muscle.1
The onset of action after administration of RYZUMVI generally occurs in 30 minutes, with the maximal effect seen in 60 to 90 minutes, and the effect lasting at least 24 hours.1
Now
available
Redefine the patient experience
post-dilation
Offer your patients the only commercially
available FDA-approved product that reverses pharmacologically-induced mydriasis.1
RYZUMVI is the first and only relatively non-selective alpha-1 and alpha-2 adrenergic antagonist approved to reverse pharmacologically-induced mydriasis.1
RYZUMVI reversibly binds to alpha-1 adrenergic receptors on the radial iris dilator muscle, thereby reducing pupil diameter, and indirectly reverses mydriasis induced by muscarinic antagonist effects on the iris sphincter muscle.1
The onset of action after administration of RYZUMVI generally occurs in 30 minutes, with the maximal effect seen in 60 to 90 minutes, and the effect lasting at least 24 hours.1
Available at these Authorized Distributors:
Important Safety Information
Warnings and Precautions
- Uveitis: RYZUMVI is not recommended to be used in patients with active ocular inflammation (e.g., iritis).
- Potential for Eye Injury or Contamination: To avoid the potential for eye injury or contamination, care should be taken to avoid touching the vial tip to the eye or to any other surface.
Indication
RYZUMVI™ (phentolamine ophthalmic solution) 0.75% is indicated for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents.
Important Safety Information
Warnings and Precautions
- Uveitis: RYZUMVI is not recommended to be used in patients with active ocular inflammation (e.g., iritis).
- Potential for Eye Injury or Contamination: To avoid the potential for eye injury or contamination, care should be taken to avoid touching the vial tip to the eye or to any other surface.
- Use with Contact Lenses: Contact lens wearers should be advised to remove their lenses prior to the instillation of RYZUMVI and wait 10 minutes after dosing before reinserting their contact lenses.
Adverse Reactions
The most common adverse reactions that have been reported are instillation site discomfort (16%), conjunctival hyperemia (12%), and dysgeusia (6%).
Click here for full Prescribing Information.
Reference: 1. RYZUMVI (phentolamine ophthalmic solution). Prescribing Information. Ocuphire.